22 Jul Catalent Pharma Solutions
Rupa Pike, Ph.D., Sr. Director, Global Head of Strategic Alliances and Field Scientists, Cell Therapy
Oct. 6 | 12:00pm | FLW Ballroom F
Somerset, New Jersey
(NASDAQ: CTLT)
Catalent Cell & Gene Therapy is an industry-leading Contract Development and Manufacturing Organization (CDMO) for advanced therapeutics.
With extensive experience in viral vector development, scale-up, and manufacturing of gene therapies, Catalent serves as a full-service CDMO for plasmid DNA, adeno-associated viral (AAV), lentiviral, and other viral vectors, oncolytic viruses, and live virus vaccines. Additionally, with our advanced technologies and expertise in both autologous and allogeneic development and manufacturing, as well as experience across a wide variety of cell types including CAR-T, TILs, NKs, iPSCs, and MSCs, Catalent is your full-service CDMO partner for cell therapy. As an experienced and innovative partner, Catalent Cell & Gene Therapy boasts a global network of dedicated clinical and commercial manufacturing facilities, including an FDA-licensed viral vector facility and fill/finish capabilities located in both the U.S. and Europe.
